1. Issues in the Management of Hemophilia: A Best Practice Series

2. Optimizing Prophylaxis in Children With Hemophilia

4. This program will include a discussion of off-label treatments and investigational agents not approved by the FDA for use in the US.

5. Introduction

6. Case 1 Newly Diagnosed Hemophilia

7. Classification of Hemophilia

8. When to Start Primary Prophylaxis

9. Origin of Prophylaxis for Hemophilia A

10. How to Start Primary Prophylaxis

11. Challenges With Venous Access

12. Trends in CVAD Use

13. Options for Factor Replacement

14. New Recombinant Factor Concentrate

15. EHL Factor Products

16. Adoption of EHL Factor Into Practice

17. Approach in Other Countries

18. Inhibitors

19. Monitoring for Inhibitor Formation

20. The SIPPET Study

21. SIPPET Implications for Previously Untreated Patients

22. SIPPET Implications for Existing Patients

23. Case 2 Boy With High-Titer Inhibitor

24. ITI Study

25. When to Start ITI

26. Treating Bleeds in Patients With High Titer

27. Case 3 Bleeding in a Teenager

28. Prophylaxis Adherence in Teenagers

29. Conclusions

30. Abbreviations

31. Abbreviations